Targeted Biomarker Tools Signosis offers a broad portfolio of cytokine and hormone ELISAs, TF profiling arrays, EMSAs, and stable reporter cell lines enabling biomarker discovery and translational biomarker validation, presenting opportunities to upsell assay kits, custom panels, and cell-line services to pharma and biotech researchers prioritizing biomarker-driven programs.

Custom Assay Development With custom assay development and stable cell line services, Signosis can tailor platforms to customer-defined pathways and targets, opening a path for lead identification partnerships, bespoke screening assays, and collaborative R&D programs with drug discovery teams.

Accelerated Screening A diverse suite of stable cell lines for RTKs and GPCRs including EGFR, HER2, FLT3 mutants, GLP‑1R, and GIPR supports rapid pathway mapping and compound screening, offering sales opportunities around high-throughput compatible platforms for early-phase drug discovery.

Global Research Footprint Signosis serves researchers worldwide with integrated in-house R&D, manufacturing, and QC, suggesting potential for expanding international distribution, service partnerships, and localized support to accelerate adoption in diverse markets.

Affordability and Speed Emphasizing sensitive, rapid, and affordable platforms positions Signosis to target budget-conscious labs and contract research organizations seeking cost-effective assays and quick turnaround for biomarker validation and translational studies.